Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts
Interleukin (IL-) 6 is a key factor in the inflammatory processes of rheumatoid arthritis. Several biologic agents target the IL-6 signaling pathway, including sarilumab, a monoclonal antibody that blocks the IL-6 receptor and inhibits IL-6-mediated cis- and trans-signaling. A careful analysis of th...
| Main Authors: | , , , , , , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
MDPI AG
2022-06-01
|
| 叢編: | Pharmaceutics |
| 主題: | |
| 在線閱讀: | https://www.mdpi.com/1999-4923/14/7/1390 |